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Cytokine storm during viral infection is a prospective
predictor of morbidity and mortality, yet the cellular
sources remain undefined. Here, using genetic and
chemical tools to probe functions of the S1P1 re-
ceptor, we elucidate cellular and signaling mecha-
nisms that are important in initiating cytokine storm.
Whereas S1P1 receptor is expressed on endothelial
cells and lymphocytes within lung tissue, S1P1 ago-
nism suppresses cytokines and innate immune cell
recruitment in wild-type and lymphocyte-deficient
mice, identifying endothelial cells as central regula-
tors of cytokine storm. Furthermore, our data reveal
immune cell infiltration and cytokine production as
distinct events that are both orchestrated by endo-
thelial cells. Moreover, we demonstrate that sup-
pression of early innate immune responses through
S1P1 signaling results in reduced mortality during
infection with a human pathogenic strain of influenza
virus. Modulation of endothelium with a specific
agonist suggests that diseases in which amplifica-
tion of cytokine storm is a significant pathological
component could be chemically tractable.
INTRODUCTION
Morbidity and mortality caused by severe influenza infections
reflect properties that are intrinsic to the virus strain, including
replication potential, receptor usage, and cytopathic effects on
pulmonary epithelial cells (Garcı´a-Sastre, 2010; Tscherne and
Garcı´a-Sastre, 2011). In addition to viral-intrinsic factors, host-
specific traits such as divergent susceptibilities to infection as
well as differences in host immune responses may ameliorate
or exacerbate both infection and clinical outcome. An overly
aggressive innate response, with early recruitment of inflamma-980 Cell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc.tory leukocytes to the lung, was a key contributor to the
morbidity of the 1918 influenza infection (Kobasa et al., 2007).
More recent clinical literature on avian H5N1 infection docu-
mented a significant association between excessive early cyto-
kine responses, immune cell recruitment, and poor outcome
(de Jong et al., 2006). Public health approaches to influenza
pandemics have relied primarily on preventative vaccine strate-
gies and supportive measures, including the use of antiviral ther-
apies. Nevertheless, the speed at which the 2009H1N1 influenza
virus swine pandemic spread during the lag of vaccine avail-
ability highlighted the need to identify additional mechanisms
for amelioration of influenza virus infection (Openshaw and
Dunning, 2010). Antiviral drugs inhibiting virus replication may
select for mutational escape, rendering the therapy ineffective.
Modulation of the host immune response has the potential
advantage of exerting less-selective pressure on viral popula-
tions. Though the prospect of blunting cytokine storm is enticing,
a major limitation to treating diseases in which cytokine storm
contributes to pathogenesis is the limited understanding of the
cellular triggers of this process. Thus, we sought to define
cellular signaling pathways that are chemically tractable to test
the hypothesis that modulating cytokine storm would provide
insight into influenza pathogenesis, with potential therapeutic
implications.
Chemical modulators of the sphingosine-1-phosphate (S1P)
signaling system have provided insight into immune cell traf-
ficking and immune responses (Rivera et al., 2008; Rosen
et al., 2009). Due to the immunomodulatory properties of S1P
receptor signaling, chemical agonists have been used success-
fully for the treatment of relapsing and remitting multiple scle-
rosis (Brinkmann et al., 2010). Though the systems biology of
the S1P receptors is complex, with five receptor subtypes, differ-
ential expression, coupling, attenuation, and catabolism (Rosen
and Liao, 2003), the availability of selective chemical probes
together with mouse genetic models allows detailed insights
into immunopathogenesis. We previously showed that a non-
selective S1P receptor agonist inhibited cytokine storm,
dendritic cell migration, and subsequent antigen-specific T cell
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Figure 1. S1P1 Receptor Agonism Suppresses Early Proin-
flammatory Cytokine and Chemokine Production and Innate
Immune Cell Recruitment during Influenza Virus Infection
Mice were infected with 13 104 PFUWSN influenza virus, and vehicle (water),
AAL-R (0.2 mg/kg) (1 hr postinfection), or CYM-5442 (2 mg/kg) (1,13, 25, and
37 hr postinfection) were administered i.t. to mice.
(A) Proinflammatory cytokines and chemokines were measured 48 hr post-
infection in BALF by ELISA.
(B) Total numbers of innate immune cells were quantified from collagenase-
digested lungs by flow cytometry at 48 hr postinfluenza virus infection.
(C) Histograms (left) and mean fluorescent intensity (MFI) (right) of CD69
expression onmacrophageswas quantified on vehicle, AAL-R-, or CYM-5442-
treated mice 48 hr postinfluenza virus infection by flow cytometry staining.
(D) Histograms (left) and MFI (right) of NK cell CD69 expression quantified as
in (C).
Data represent average ± SEM from four to mice per group. *p < 0.05;
**p < 0.005; ***p < 0.0005. Results are representative of greater than six
independent experiments. See also Figure S1 and Figure S2.proliferation, protecting the lung tissue from host-mediated
injury. Alleviation of immunopathology by the nonselective S1P
receptor agonist did not affect virus clearance nor the production
of neutralizing antibodies, demonstrating that, although cytokine
storm was diminished, retention of a sufficient cellular and
humoral immune response, as well as long-term protective
immunity, still occurs (Marsolais et al., 2008; Marsolais et al.,
2009).
Here, through the use of an S1P1 receptor subtype-selective
agonist as well as genetic and biochemical tools, we define
a crucial endothelial signaling loop that is important for the initi-
ation of cytokine storm. We reveal that cytokine secretion and
immune cell infiltration are separable events that are both regu-
lated by the pulmonary endothelium. Further, we demonstrate
that suppression of early innate immune responses through
S1P1 signaling results in reduced mortality during human path-
ogenic influenza virus challenge. Thus, S1P1 receptor signaling
in endothelium provides a mechanism for attenuation of influ-
enza virus-induced morbidity and reveals an unexpected role
for endothelial cells as regulators of cytokine storm.
RESULTS
Administration of an S1P1 Agonist Blunts Cytokine
Storm
Previously, we reported that treatment of influenza virus-infected
mice with AAL-R, a promiscuous S1P receptor agonist for S1P1
and S1P3–5 receptors, inhibits early proinflammatory cytokine
expression and innate immune cell accumulation within the
lung (Marsolais et al., 2008; Marsolais et al., 2009). To assess
the contribution of S1P1 receptor signaling in inhibition of influ-
enza virus-induced early inflammation, infected mice were
treatedwith the S1P1 receptor-specific agonist CYM-5442 (Gon-
zalez-Cabrera et al., 2008). Treatment with 2 mg/kg of CYM-
5442 twice daily significantly inhibited secretion of cytokines
and chemokines associated with influenza virus-induced path-
ology, including IFN-a, CCL2, IL-6, TNF-a, and IFN-g (Figure 1A)
in addition to CCL3, CCL5, CXCL2, and IL-1a (Figure S1A),
compared to vehicle-treated mice 48 hr postinfection. CYM-
5442 reduction of IFN-a, CCL2, CCL3, CCL5, IL-1a, and IL-6
expression was as complete as treatment with the promiscuous
agonist; however, it was not as effective as AAL-R in suppressing
CXCL2, TNF-a, and IFN-g (Figure 1A and Figure S1A), suggest-
ing a role for other S1P receptors in modulating those cyto-
kines. In addition to inhibiting cytokine/chemokine production,
AAL-R and CYM-5442 administration to influenza virus-infected
mice blunted the accumulation of innate inflammatory infiltrate
characterized as macrophages/monocytes (CD11b+, F480+,
Ly6G), neutrophils (CD11b+, LyG6+, F480), and NK cells
(NK1.1+, CD3), although AAL-R was more effective at inhibiting
macrophage/monocyte and NK cell accumulation in the lung
(Figure 1B). We also observed significantly reduced CD69
expression on macrophage/monocytes and NK cells following
treatment with either CYM-5442 or AAL-R 48 hr postinfection,
demonstrating diminished cell activation (Figures 1C and 1D).
Despite significant blunting of innate immune cell recruitment
and cytokine/chemokine responses, we observed no differences
in viral titers following AAL-R or CYM-5442 treatment comparedCell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc. 981
CD69+ Macrophages
      & monocytes
CD69+ NK cells
0
0.5
1.0
1.5
2
Vehicle
CYM-5442
T
o
t
a
l 
#
 
o
f
 
c
e
ll
s
 
in
 
t
h
e
 
lu
n
g
o
f
 
C
5
7
B
L
/
6
J
 
m
ic
e
 (
x
 
1
0
5
)
 
IFN- CCL2 CCL5 CXCL10 IL-6 IL-1
0
100
200
300
400
500
1000
1500
2000
Vehicle
CYM-5442
Cytokines/Chemokines
p
g
/
m
l
 
i
n
 
t
h
e
 
B
A
L
F
 
o
f
 
C
5
7
B
L
/
6
J
 
m
i
c
e
BA
IFN- CCL2 CCL5 CXCL10 IL-6 IL-1
0
100
200
300
400
500
1000
1500
2000
Vehicle
RP-002
Cytokines/Chemokines
p
g
/
m
l
 
i
n
 
t
h
e
 
B
A
L
F
o
f
 
C
5
7
B
L
/
6
J
 
m
i
c
e
C
CD69+ Macrophages/
        monocytes
CD69+ NK cells
0
0.5
1.0
1.5
2.0
Vehicle
T
o
t
a
l 
#
 
o
f
 
c
e
ll
s
 
in
 
t
h
e
 
lu
n
g
o
f
 
C
5
7
B
L
/
6
J
 
m
ic
e
 
(
x
1
0
5
)
D
***
**
**
*
***
**
**
**
**
**
*
**
**
*
**
 *
RP-002
α
α α
α
Figure 2. S1P1 Receptor Agonism Suppresses Early Proinflammatory Cytokine and Chemokine Production and Recruitment of Activated
Innate Immune Cells during Human Pathogenic H1N1:2009 Swine Influenza Virus Infection
(A–D) Mice were infected with 1 3 105 PFU A/Wisconsin/WSLH34939/09 influenza virus, and either vehicle (water), CYM-5442 (2 mg/kg) (1, 13, 25, and 37 hr
postinfection), or RP-002 (2 mg/kg on 1 and 25 hr postinfection) were administered i.t. to mice. Proinflammatory cytokines and chemokines were measured 48 hr
postinfection in BALF by ELISA in either CYM-5442- (A) or RP-002-treated mice (C). Total numbers of innate immune cells were quantified from collagenase-
digested lungs by flow cytometry at 48 hr postinfluenza virus infection inmice treatedwith either CYM-5442 (B) or RP-002 (D). Data represent average ±SEM from
four to five mice per group. *p < 0.05; **p < 0.005; ***p < 0.0005. Results are representative of two independent experiments. See also Figure S3.to vehicle-treated mice (Figure S2), demonstrating that S1P1
agonism neither inhibits nor enhances viral replication. Collec-
tively, these results reveal that activation of a single sphingo-
sine-1-phosphate receptor, S1P1, is sufficient to blunt global
innate inflammation following mouse-adapted influenza virus
infection in mice.
We next asked whether S1P1 receptor agonism could sup-
press early innate cytokine and chemokine responses following
infection with a human pathogenic isolate of influenza virus. To
test this, we infected mice with a virulent isolate of the 2009
H1N1 pandemic influenza virus that was isolated from a hospi-
talized patient and has never been passaged through mice
(A/Wisconsin/WSLH34939/09) (Itoh et al., 2009). Infection of
C57BL/6J mice with this strain causes severe disease, resulting
in rapid mortality beginning between days 4 and 6 postinfection
(data not shown). Similar to infection with mouse-adapted WSN
influenza virus, treatment with CYM-5442 following infectionwith
H1N1:2009 significantly suppressed cytokine and chemokine
responses and the accumulation of activated innate immune
cells 48 hr postinfection (Figures 2A and 2B). We also tested
an additional S1P1 receptor-selective agonist (RP-002) to pro-
vide support for S1P1 receptor specificity and to show directly
that S1P1-selective agonists share this modulation of innate
immunopathology. We infected mice with H1N1:2009 pandemic
influenza virus as above and treated mice with RP-002 at 1
and 25 hr postinfection. Similar to what we observed with982 Cell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc.CYM-5442, RP-002 treatment significantly inhibited the pro-
duction of multiple proinflammatory cytokine and chemokines
(Figure 2C) and suppressed the accumulation of activated
(CD69+) macrophages/monocytes and NK cells in the infected
lung 48 hr postinfection (Figure 2D). Moreover, RP-002-medi-
ated suppression of innate immune cell recruitment and cyto-
kine/chemokine production occurred without altering lung viral
titers (Figure S3), demonstrating that S1P1 agonist-mediated
suppression of cytokines and chemokines is not due to direct
effects on influenza virus replication.
S1P1 Agonist-Mediated Suppression of Early Innate
Immune Responses Results in Protection to Human
Pathogenic Influenza Virus Challenge in Mice
Early dysregulated innate immune responses in the lung have
been associated with morbidity and mortality during infection
with highly pathogenic strains of influenza virus (Cillo´niz et al.,
2009; Kobasa et al., 2007). Therefore, we askedwhether blunting
early innate cytokine/chemokine responses using an S1P1
agonist could protect mice from lethal infection with a virulent
human isolate of pandemic 2009 H1N1 that had not been
passaged in mice (A/Wisconsin/WSLH/34939/09). In order not
to impose additional stress on the infected lung and because
oral delivery is a popular route for drug administration, we
orally administered the S1P1 agonist, RP-002, at 6 mg/kg
by gavage to C57BL/6J mice infected with 1 3 105 PFU of
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Figure 3. Oral Administration of an S1P1 Agonist Suppresses Early
Innate Cytokine and Chemokine Production and Significantly
Improves Survival to Lethal Infection with H1N1 2009 Swine Influ-
enza Virus
Micewere infectedwith 23 105 PFUA/Wisconsin/WSLH34939/09 and treated
by gavage with either vehicle (water) or RP-002 (6 mg/kg on 1 and 25 hr
postinfection for cytokine and cell recruitment assays at 48 hr, with a third dose
administered at 49 hr for the 16 day survival experiment).
(A) Levels of proinflammatory cytokines and chemokines were analyzed in the
BALF 48 hr postinfection by ELISA.
(B) Total numbers of activated (CD69+) macrophages/monocytes and NK cells
were detected in collagenase-digested lungs 48 hr postinfection by flow
cytometry.
(C) Mice were monitored daily for survival for 16 days postinfection.
For (A) and (B), data represent the average ±SEMof four to fivemice per group,
whereas (C) had ten mice per group. *p < 0.05; **p < 0.005; ***p < 0.0005.
Data are representative of three independent experiments. See also Figure S3.A/Wisconsin/WSLH/34939/09 at 1 and 25 hr postinfection.
RP-002 significantly suppressed cytokine amplification (Fig-
ure 3A) as well as recruitment of myeloid cells to the infected
lung, as measured by flow cytometry (Figure 3B).
Early administration of RP-002 resulted in enhanced survival
time after lethal challenge with A/Wisconsin/WSLH/34939/09,
with death initiating in vehicle-treated mice on day 6 postin-
fection compared to day 11 postinfection for RP-002-treated
mice (Figure 3C, p < 0.005). Moreover, RP-002 treatment re-
sulted in significant improvement in overall survival compared
to vehicle-treated mice (20% mortality in RP-002 versus
80% mortality for vehicle, p < 0.005; Figure 3C). These findings
demonstrate a significant biological phenotype resulting from
early S1P1 receptor agonist treatment following pathogenic
influenza virus infection. By showing directly that aborting an
early step in cytokine amplification significantly protects against
an ordinarily lethal human pathogenic H1N1:2009 infection,
the findings expand previous observations of an association
between humans and animal models in which dysregulation of
innate immune responses contributes tomorbidity andmortality.
Importantly, treatment with RP-002 ameliorated morbidity and
mortality associated with human pathogenic H1N1:2009 severe
influenza infection. Effects upon survival are in keeping with our
previously published data (Marsolais et al., 2009) that this mech-
anism does not alter virus-specific neutralizing antibody re-
sponse, affinity maturation, and class switching. This documents
that the cytokine storm plays a direct and cardinal role in influ-
enza-mediated lung disease. We then sought to delineate the
mechanism of S1P1 suppression of cytokine amplification.
S1P1 Is Expressed on Pulmonary Endothelium
and Lymphocytes
To identify cells in the lung that express the S1P1 receptor, we
utilized an eGFP-S1P1 receptor knockin mouse in which the
native S1P1 receptor was homologously replaced with a func-
tional enhanced green fluorescent protein (eGFP)-tagged S1P1
receptor (S1P1-eGFP) (Cahalan et al., 2011). This mouse model
allowed direct detection of eGFP-S1P1 receptor protein expres-
sion by flow cytometry, with additional biochemical confirmation
using highly specific antibodies for GFP followed by western
blotting that distinguishes the fused S1P1-eGFP receptor by
specific molecular weight. High levels of S1P1-eGFP were de-
tected on lung lymphatic (CD45, CD31+, gp38+) and vascular
(CD45, CD31+, gp38) endothelium, whereas pulmonary epi-
thelium (CD45, CD31, EpCAM+) was negative for S1P1-eGFP
(Figure 4A). As reported previously, CD4+ T cells (CD4+, CD3+),
CD8+ T cells (CD4+, CD3+), and B cells (B220+, CD19+) ex-
pressed S1P1-eGFP (Figure 4B), whereas leukocytes, including
macrophages/monocytes, a subset of alveolar macrophages
(F480+, CD11c+, CD11b), dendritic cells (CD11c+, I/A-I/E+,
CD205+, F480), neutrophils, NK cells (NK1.1+, CD3-), and innate
lymphoid cells (LinSca1+), expressed negligible levels of
S1P1-eGFP (Figure 4C and data not shown). Cells from unin-
fected mice expressed similar levels of S1P1-eGFP as infected
mice, demonstrating that S1P1 receptor expression is not altered
following influenza virus infection (Figure 4D). To confirm the
S1P1-eGFP expression pattern, a western blot for S1P1-eGFP
was performed on cells FACS sorted from the lungs of infectedCell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc. 983
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Figure 4. S1P1 Receptor Is Expressed on Pulmonary Endothelium and Lymphocytes, but Not on Pulmonary Epithelial Cells
(A–C) Flow cytometry histograms showing eGFP fluorescence from heterozygous S1P1-eGFP on lung endothelial and epithelial cells. (A) CD4 andCD8 T cells and
B cells. (B) Macrophages, neutrophils, dendritic cells, and NK cells (C) prior to influenza virus infection.
(D) Relative expression of S1P1-eGFP on lung cell populations before or 48 hr after influenza virus infection. The numbers in the upper-right corner of each plot
represent the relative eGFP expression as calculated by dividing theMFI of eGFP on S1P1-eGFP transgenic mice over eGFPMFI of C57BL/6J littermate controls.
Data represent average ± SD from two to five mice per group. Results are representative of three independent experiments. See also Figure S4.
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Figure 5. S1P1 Receptor Agonism Suppresses Early Proin-
flammatory Immune Responses Independently of Lymphocytes
Rag2/mice were infected and treated with either vehicle or CYM-5442, as in
Figure 1.
(A) Proinflammatory cytokines and chemokines were measured in BALF by
ELISA 48 hr postinfluenza infection.
(B) Total numbers of innate immune cell recruitment were quantified from
collagenase-digested lungs by flow cytometry at 48 hr postinfluenza virus
infection.
Data represent average ± SEM from fivemice per group. *p < 0.05; **p < 0.005;
***p < 0.0005. Results are representative of two independent experiments. See
also Figure S1 and Figure S5.and uninfected mice. Endothelial cells, T cells, and B cells were
positive for S1P1-eGFP in uninfected mice, confirming our flow
cytometry results (Figure S4A). However, though S1P1-eGFP
was detected by western blot in B cells from uninfected mice,
we did not detect S1P1-eGFP expression by western Blot in
influenza virus-infected lung-resident B cells (Figure S4A). We
did not detect S1P1-eGFP expression by western blot in epithe-
lial cells, macrophages/monocytes, and alveolar macrophages
either before or after influenza virus infection (Figure S4A). More-
over, CYM-5442 treatment of infected S1P1-eGFP knockin mice
did not diminish expression of S1P1-eGFP on endothelial cells,
T cells, or B cells, demonstrating that administration of this
S1P1-specific agonist does not induce degradation of the S1P1
receptor (Figure S4B). Therefore, CYM-5442 does not exert an
antagonistic effect due to receptor degradation, demonstrating
functional agonism of S1P1 as the mechanism by which CYM-
5442 suppresses cytokine storm.
Inhibition of Cytokine Storm Is Not Due to Lymphocyte
S1P1 Receptor Activation
Lymphocytes and pulmonary endothelium are the only cells
within the lung that express measurable amounts of S1P1-eGFP
as detected by flow cytometry and western blot. It is plausible
that lymphocytes within the lung provide a bystander effect
during the innate immune response to influenza virus infec-
tion. To rule out a role for lymphocytes during S1P1 receptor-
mediated inhibition of inflammation following influenza virus in-
fection, lymphocyte-deficient Rag2/ mice were infected and
treated with vehicle or CYM-5442. Administration of CYM-
5442 to influenza virus-infected Rag2/ mice resulted in signif-
icant inhibition of expression of IFN-a, CCL2, IL-6, TNF-a, and
IFN-g (Figure 5A), in addition to CCL5, CXCL2, and CXCL10
(Figure S1B). Atypical lymphocyte populations that could,
in principal, contribute to suppression of cytokine production
did not express S1P1-eGFP and thus also do not con-
tribute to this mechanism. Inflammatory cell infiltrates, including
macrophages/monocytes and NK cells, were significantly
reduced in CYM-5442-treated Rag2/ mice (Figure 5B).
Reduced numbers of neutrophils were also observed within
the infected lung, but the difference was not statistically signifi-
cant (Figure 5B). Moreover, lung-infiltrating macrophages and
NK cells in Rag2/ mice were less activated, as measured by
CD69 surface expression (Figure S5). CYM-5442 treatment of
influenza virus-infected lymphocyte-deficient mice inhibits the
innate inflammatory response, excluding a role for lymphocytes
as key regulators of influenza virus-induced cytokine storm.
S1P1 Receptor Agonism Suppresses Immune Cell
Recruitment through Downregulation of Chemokine
Production by Lung Endothelial Cells
The strong expression of S1P1-eGFP receptor on pulmonary
endothelium, coupled with the inhibition of cytokine storm in
RAG2/ mice, suggests that S1P1 receptor signaling in lung
endothelial cells suppresses cytokine storm. Endothelial cells
have been shown to produce various cytokines and chemokines
during inflammatory processes and may be a source of cyto-
kines and chemokines in the lung during influenza virus infection.
To evaluate the effects of CYM-5442 treatment on pulmonaryendothelial cell cytokine and chemokine production, we purified
lung endothelial cell populations and performed mRNA and
protein analyses. Endothelial cells expressed elevated levels of
the chemokines CCL2, CCL5, and CXCL10 at the mRNA level
(Figure 6A). Importantly, treatment with CYM-5442 significantly
reduced mRNA expression of chemokines in lung endothelial
cells compared to vehicle-treated mice early after influenza virus
infection (Figure 6A). Examination of chemokine production in
purified lung vascular and lymphatic endothelial cells revealed
a significant reduction in chemokine production at the protein
level after CYM-5442 treatment (Figure 6B). Analysis of pulmo-
nary endothelial cell integrin expression did not show appre-
ciable differences in mice infected with influenza virus treated
with vehicle compared to CYM-5442 (Figure S6).
Because chemokine presentation on endothelial cells is
crucial for leukocyte activation and extravasation into infected
tissue, we asked whether reduction of chemokine expression
following CYM-5442 treatment resulted in reduced entry of in-
flammatory cells into the infected lung. For these experiments,Cell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc. 985
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Figure 6. S1P1 Receptor Agonism Actively Suppresses Recruitment of Innate Immune Cells through Downregulation of Chemokine
Expression on Lung Endothelial Cells
(A) Relative mRNA expression of chemokines from purified lung endothelial cell populations at 36 hr postinfluenza virus infection.
(B) Protein expression of CCL2 and CXCL10 measured by ELISA on FACS-purified vascular and lymphatic lung endothelial cells 48 hr postinfluenza virus
infection.
(C) LysM-GFP mice were infected with 1 3 104 PFU of influenza virus. At 2 days later, bone marrow cells were harvested from infected LysM-GFP mice and
transferred intoC57BL/6Jmice thatwere either left uninfectedor infectedwith13 104PFUof influenza virus 2 hr prior.Mice receiving bonemarrowcells fromLysM-
GFP-positivemicewere treatedwitheither vehicleorCYM-5442 (2mg/kg1,13, 25,and37hrpostinfection), andat 48hrpostinfection, total lungcellswereharvested
from lung homogenates and the total numbers of GFP-expressing granulocytes (CD11b+, Ly6G+) and macrophages/monocytes (CD11b+F480+) were quantified.
(D) Total number of LysM-GFP-positive granulocytes and macrophages/monocytes per lung of uninfected or infected mice treated with either vehicle or
CYM-5442.
(E) Exogenous intratracheal administration of chemokine restores recruitment of innate immune cells. However, it does not resurrect cytokine/chemokine
production after CYM-5442 treatment. Mice were infected with 13 104 PFUWSN influenza virus, and either vehicle (water) or CYM-5442 (2 mg/kg 1, 13, 25, and
37 hr postinfection) were administered to mice i.t. Following administration of CYM-5442, recombinant mouse CCL2 was administered (50 mg) i.t. directly into the
lungs. The bar graph shows the total numbers of macrophages/monocytes, neutrophils, and NK cells in the lung 48 hr postinfluenza virus infection.
(F) Proinflammatory cytokines and chemokines were measured in BALF 48 hr postinfection by ELISA in mice treated with vehicle, CYM-5442, or CYM-5442 +
rmCCL2, as in (E).
Data represent average ± SEM from five mice/group. *p < 0.05; **p < 0.005; ***p < 0.0005. Results are representative of two independent experiments. See also
Figure S1 and Figure S6.
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we used LysM-GFP mice in which macrophages, monocytes,
and neutrophils express green fluorescent protein, allowing us
to track these cell populations after adoptive transfer into con-
genic C57BL/6J mice. We infected LysM-GFP mice with influ-
enza virus and 48 hr later purified bone marrow cells for adoptive
transfer. 53 106 LysM-GFP bone marrow cells were transferred
into influenza virus-infected C57BL/6J mice treated with either
vehicle or CYM-5442 (Figure 6C). The lungs of infected or
uninfected C57BL/6J mice receiving LysM-GFP cells were
then harvested 48 hr postinfection, and the numbers of GFP-
positive cells in the lung were quantified. Treatment with CYM-
5442 resulted in significantly reduced recruitment of both GFP-
positive neutrophils (CD11b+ F480 Ly6G+) and macrophages/
monocytes (CD11b+ Ly6G F480+) into the lung (Figure 6D).
Therefore, CYM-5442 treatment inhibits the infiltration of circu-
lating inflammatory cells into the lung.
S1P1 receptor signaling is associated with enhanced capillary
integrity (Rosen et al., 2007), whereby S1P1 receptor antagonists
induce vascular leakage (Rosen et al., 2008; Sanna et al., 2006),
and S1PR-selective agonists protect from vascular leakage
induced by exogenous administration of VEGF (Sanchez et al.,
2003). Though myelomonocytic recruitment is not modulated
by endothelial permeability changes, we formally assessed
whether suppression of inflammatory cell recruitment to the
lung reflected a passive inhibition of leukocyte recruitment or
whether suppression of chemokines on lung endothelial cells
limits innate immune cell recruitment. Rescue experiments
were performed in which mice were infected with influenza in
the presence or absence of intratracheal administration of re-
combinant murine CCL2 (rmCCL2), with or without CYM-5442
treatment. Administration of rmCCL2 to infected mice treated
with CYM-5442 restored macrophage/monocyte and NK cell
numbers in the lung to levels equivalent to infected mice treated
with vehicle (Figure 6E) 48 hr postinfection. These data demon-
strate that CYM-5442 inhibition of cellular infiltration into the
lung is not due to the enhancement of endothelial cell barrier
function but due to suppression of chemokine production.
Therefore, S1P1 receptor agonism suppresses endothelial cell
chemokine expression, resulting in diminished cell infiltration.
Despite the rescue of CCL2 levels in the BALF and the res-
toration of macrophage/monocyte recruitment into the lung of
CYM-5442-treated mice, global cytokine and chemokine pro-
duction was not restored (Figure 6F and Figure S1C). Influenza
virus infection of CCR2-deficient mice results in substantial
reductions of infiltrating macrophages/monocytes (Dawson
et al., 2000). To rule out infiltrating macrophages, we infected
CCR2-deficient mice with WSN influenza virus as done above
and treated with either vehicle or CYM-5442. Infection of
CCR2-deficient mice resulted in significantly reduced numbers
of macrophages/monocytes without altering neutrophil or NK
cell numbers in the lung 48 hr postinfection (Figure S7A). Despite
reduced levels of macrophages/monocytes in the lung, we still
detected significant levels of IFN-a, CCL2, CCL3, CCL5,
CXCL2, CXCL10, IL-1a, IL-6, and IFN-g (Figure S7B). More
importantly, treatment of CCR2-deficient mice with CYM-5442
still significantly reduced all cytokines and chemokines tested
at 48 hr postinfection except for CCL5 (Figure S7B). Failure to
inhibit cytokine and chemokine production in CCR2-deficientmice or to re-establish cytokine and chemokine production by
the induction of macrophage/monocyte cell infiltration through
rmCCL2 administration following CYM-5442 treatment suggests
that monocytes andmacrophages are not major sources of early
cytokine and chemokine production. Furthermore, these data
indicate that cell recruitment and cytokine responses may be
uncoupled events.
Proinflammatory Cytokine Responses Are Independent
of Innate Immune Cell Recruitment and Dependent on
Type I Interferon Signaling
Infiltration of macrophages and NK cells alone does not appear
to be associated with cytokine storm. Therefore, we evaluated
the contribution of total inflammatory cell infiltration to cytokine
production during influenza virus infection. Mice were treated
with an anti-CD11b antibody (M7/80) that has been shown to
inhibit the recruitment of CD11b-expressing cells into inflamed
tissues (Rosen and Gordon, 1987). Though treatment with anti-
CD11b significantly inhibited the recruitment of macrophages/
monocytes, neutrophils, and NK cells into the lung (Figure 7A),
we observed no reduction in levels of proinflammatory cyto-
kines/chemokines, other than IFN-g (Figure 7B), which is prob-
ably a direct result of diminished infiltration of NK cells, the
primary source of IFN-g at this time point. Moreover, treatment
with CYM-5442 significantly inhibited the production of IFN-a,
CCL2, IL-6, TNF-a, and IFN-g (Figure 7B), in addition to CCL3,
CCL5, CXCL2, CXCL10, and IL-1a (Figure S1D) in anti-CD11b-
treated mice. These results further demonstrate that innate cell
recruitment and cytokine production are independent events
early after influenza virus infection, both which are inhibited by
S1P1 receptor agonism of pulmonary endothelial cells. Impor-
tantly, our data demonstrate that inflammatory cell infiltration
into the lung is not required for cytokine and chemokine produc-
tion. An additional line of evidence excluding hematopoietic cells
from S1P1 agonist-mediated reduction of early innate cytokine
and chemokine responses following influenza virus infection
was provided by irradiation resistance of S1P1 agonist suppres-
sion. C57BL/6Jmicewere irradiatedwith 500 rads and 24 hr later
infected with WSN influenza virus and treated with either vehicle
or CYM-5442. Irradiation reduced CD45+ hematopoietic cells in
lung by 90% (vehicle: 23 107 cell/lung versus 500 rads: 23 106
cells/lung), and importantly, treatment of irradiated mice with
CYM-5542 significantly reduced the levels of IFN-a (irradiated
vehicle: 86 pg/ml versus irradiated CYM-5442: 17.9 pg/ml,
p = 0.0006), CCL2 (irradiated vehicle: 944 pg/ml versus irradiated
CYM-5442: 452 pg/ml, p = 0.00002), CXCL10 (irradiated vehicle:
204 pg/ml versus irradiated CYM-5442: 83 pg/ml, p = 0.00003),
and IL-6 (irradiated vehicle: 170 pg/ml versus irradiated CYM-
5442: 70 pg/ml, p = 0.0001), demonstrating that a radiation-
resistant cell population mediated S1P1 receptor-mediated sup-
pression of the inflammatory response. These results, coupled
with the restricted S1P1 receptor expression pattern, support
an important role for endothelial cells in regulating pulmonary
innate immune responses to influenza virus.
Type I interferons, predominantly IFN-a species, are elevated
early after respiratory virus infection and are thought to be crucial
for the production of proinflammatory cytokines and chemo-
kines. Our results thus far have demonstrated that CYM-5442Cell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc. 987
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Figure 7. Proinflammatory Cytokine Responses Are Independent of Innate Immune Cell Recruitment and Dependent on Type I Interferon
Signaling
(A) Total numbers of innate immune cells were quantified from lung digests by flow cytometry at 48 hr postinfluenza virus infection in mice treated 1 hr post-
infection with vehicle or CYM-5442 in the presence of either anti-CD11b or isotype control antibody (M7/80) (0.5 mg/mouse) 0 and 24 hr postinfection.
(B) Proinflammatory cytokines and chemokines were measured 48 hr postinfection by ELISA in BALF in mice treated as in (A).
(C) C57BL/6J or IFN ab receptor-deficient mice were infected with 13 104 PFU of influenza virus and treated with either vehicle or CYM-5442 (2 mg/kg 1, 13, 25,
and 36 hr postinfection. Total numbers of innate immune cells were quantified from lung digests by flow cytometry at 48 hr postinfluenza virus infection, and
(D) proinflammatory cytokines and chemokines were measured 48 hr postinfection by ELISA in BALF fluid.
Data represent average ± SEM from five mice per group. *p < 0.05; **p < 0.005; ***p < 0.0005. Results are representative of two independent experiments. See
also Figure S1 and Figure S7.treatment consistently inhibits the production of IFN-a in the lung
early after influenza virus infection (Figure 1, Figure 2, Figure 5,
and Figure 6). Therefore, we postulated that blunting IFN-a
production may be a mechanism by which CYM-5442 inhibits
cytokine storm early after influenza virus infection. To address
this, we infected IFNa/b receptor knockout mice with influenza
virus, treated these mice with either vehicle or CYM-5442, and
measured innate cell recruitment and cytokine/chemokine
production 48 hr postinfection. Significant differences were not
observed in inflammatory cell recruitment of macrophages/
monocytes, neutrophils, and NK cells into the lung of IFNa/b
receptor-deficient mice when compared to C57Bl/6J mice (Fig-
ure 7C). As seen with infected C57BL/6J mice, CYM-5442
treatment inhibited innate immune cell recruitment in IFNa/b
receptor-deficient mice 48 hr postinfection (Figure 7C). Despite
recruitment of innate immune cells into the lung of IFNa/b
receptor-deficient mice 48 hr postinfection, thesemice exhibited
significantly reduced levels of IFN-a, CCL2, IL-6, and IFN-g (Fig-
ure 7D) in addition to CCL5 and CXCL10 in the BALF fluid (Fig-
ure S1E). Taken together, our data demonstrate that regulation988 Cell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc.of cellular recruitment into the pulmonary tissue is mediated by
endothelial cells and is independent of type I interferon signaling.
Moreover, S1P1 receptor agonism of endothelial cells inhibits
IFN-a production and results in the dampening of global pro-
inflammatory cytokine responses.
DISCUSSION
The recruitment of innate immune cells into the lungs combined
with excessive proinflammatory cytokine and chemokine pro-
duction are hallmarks of influenza virus infection (La Gruta
et al., 2007). Contrary to current dogma, which places lung
epithelium and inflammatory infiltrate at the center of influenza
virus-induced cytokine storm (La Gruta et al., 2007), we demon-
strate here a central role for pulmonary endothelium in regulating
this process. Furthermore, we determined that both innate
immune cell recruitment and early innate cytokine and chemo-
kine production are uncoupled events, with endothelial cells
at the center of both processes. The chemical and genetic
approaches shown here have a potentially broad impact on
understanding disease pathogenesis. Early dysregulation of
innate cellular and cytokine responses predict disease severity
and death during highly pathogenic influenza virus infection
(Bermejo-Martin et al., 2009; Cillo´niz et al., 2009; de Jong
et al., 2006; Kobasa et al., 2004, 2007). The early induction of
the cytokines IFN-a, TNF-a, IL-1a, and IL-6 and the chemokines
CCL2, CCL3, CXCL2 (IL-8), and CXCL10 are associated with
symptom formation in humans (Hayden et al., 1998; Kaiser
et al., 2001). TNF-a, IL-1, and IL-6 possess multifunctional activ-
ities and are associated with morbidity during influenza virus
infection. Chemokines such as CCL2, CCL3, CXCL2, and
CXCL10 induce the recruitment of innate immune cells into the
lung, which can release more cytokines exacerbating cytokine
storm and further damage the lung. We demonstrate that
suppression of early innate immune responses through S1P1
signaling on endothelial cells results in significantly reduced
mortality during infection of mice with a human pathogenic strain
of influenza virus (Figure 3). Importantly, our results identify
a pulmonary cell type, endothelial cells, as potential targets for
suppressing excessive innate inflammatory responses.
The ability of CYM-5442 to diminish the production of IFN-a
early following influenza virus infection is broadly relevant. The
requirement of type I interferon signaling for the early production
of multiple cytokines and chemokines after influenza virus infec-
tion is striking. Moreover, production of proinflammatory cyto-
kines requires type I interferon signaling, but the type I interferon
pathway is dispensable for cell recruitment. Though type I inter-
feron signaling is well known to inhibit viral replication (Garcı´a-
Sastre and Biron, 2006), evidence also points to pathogenic
roles for IFN-a during viral infection. Several proinflammatory
cytokines and chemokines are downstream of type I interferon
receptor signaling. Moreover, disease onset correlates directly
with local respiratory production of IFN-a in humans (Hayden
et al., 1998). Thus, type I interferon signaling may play dual roles
in viral pathogenesis and viral clearance. S1P1 receptor signaling
on pulmonary endothelial cells in vivo blunts but does not abolish
IFN-a production and may explain why pathology is lessened
without compromising the host’s ability to clear the virus.
The ability of S1P1 receptor activation to suppress cytokine
and chemokine production in the lung in irradiatedmice, coupled
to the pattern of S1P1 receptor expression in the lung, strongly
indicates a central endothelial component to early innate im-
mune responses. An interesting question is whether lung lym-
phatic, vascular, or both endothelial cell populations are directly
responsible for the observed immune modulation. Moreover, of
the large receptor reserve in blood, endothelium ensures that
S1P1 receptor expression is maintained on both basolateral
and luminal surfaces of the targeted endothelial cell populations
(Cahalan et al., 2011) and retains a responsiveness to agonist.
Additional approaches to separate blood and lymphatic contri-
butions are still needed. Though we know that endothelial cells
produce chemokines, endothelial-mediated regulation of cyto-
kine production in the lung still needs to be determined. It is
possible that endothelial cells may regulate cytokine production
in the lung through a complex crosstalk mechanism with lung
epithelium or resident hematopoietic cells. Nevertheless, the
identification of endothelial cells as central orchestrators of early
innate immune-mediated inflammation is of fundamental interestand has broad implications for treating multiple diseases. The
contribution of aberrant proinflammatory cytokine and chemo-
kine production to pathogenesis has been reported for viral
and bacterial diseases, including HIV (Stacey et al., 2009), Han-
tavirus (Borges et al., 2006), severe acute respiratory syndrome
(SARS) (Thiel and Weber, 2008), and pneumococcal bacterial
pneumonia (Bergeron et al., 1998). Further, the etiology of sev-
eral autoimmune conditions has been directly associated with
excessive innate immune responses (Kawane et al., 2010; Link,
1998). Thus, understanding the cellular pathways that regulate
cytokine storm and developing appropriate chemical signaling
tools to identify pathophysiological points of control not only
provide insight intomicrobial-host interactions, but alsomay ulti-
mately reveal additional approaches to achieve effective immu-
notherapy in multiple diseases. In addition, our results present a
nonlymphopenicmechanism bywhich sphingosine analog treat-
ment suppresses pathogenic immune responses. Lastly, these
data suggest that endogenous S1P acting on endothelial S1P1
receptor could be a negative regulator of cytokine amplification
and raise the possibility that heterogeneities in S1P metabolism
between individuals could contribute to the advantages or
disadvantages conferred by genetic individuality to host survival
in a number of diseases.
EXPERIMENTAL PROCEDURES
Mice, Virus, Compounds, and Reagents
Six- to eight-week-old C57Bl/6 male mice and S1P1-eGFP mice described
elsewhere (Cahalan et al., 2011) were bred and maintained in a closed
breeding facility at The Scripps Research Institute. Influenza A/WSN/33
(WSN; H1N1) and the human H1N1 2009 isolate A/Wisconsin/WSLH34939/
09 (a kind gift from Yoshihiro Kawaoka, University of Madison, WI) were ampli-
fied and plaqued on Madin-Darby Canine Kidney (MDCK) cells. Mice were in-
fected intratracheally (i.t.) with 1 3 104 PFU of influenza A/WSN/33 virus or
intranasally with 13 105 PFU of A/Wisconsin/WSLH34939/09 under isoflurane
anesthesia. At 1 hr postinfection, mice were anesthetized by isoflurane inhala-
tion for i.t. delivery of vehicle (100 ul of water), AAL-R (0.2 mg/kg dissolved in
water), CYM-5442 (2 mg/kg dissolved in water), or RP-002 (3 mg/kg i.t. or
6 mg/kg orally dissolved in water). Multiple doses of compound were admin-
istered at the specific times listed in the figurte legends. (AAL-R and CYM-
5442 were synthesized according to published methods (Jo et al., 2005).
RP-002, (R)-2-(4-(5-(3-cyano-4-isopropoxyphenyl)-l,2,4-oxadiazol-3-yl)-2,3-
dihydro-lH-inden-l-ylamino)-N,N-dimethylacetamide hydrochloride, was syn-
thesized according to the published method (Martinborough et al., 2011).
The compound had an EC50 for S1P1 of 0.13 nM, was > 100-fold selective
versus S1P5, and was 10,000-fold selective versus S1P2, 3, and 4 respec-
tively, when assayed as described (Cahalan et al., 2011). Recombinant murine
CCL2 (rmCCL2) was purchased from Shenandoah Biotechnology Inc.
(Warwick, PA).
Cytokine and Chemokine Analysis
The trachea of euthanized mice was exposed, transected, and incubated with
a blunt 18 gauge needle. One milliliter of phosphate-buffered saline supple-
mented with Complete Mini, EDTA-free Protease Inhibitor Cocktail (Roche)
was infused and recovered four times. The recovered bronchoalveolar lavage
fluid was spun at 30003 g for 3min at 4Cand stored at80Cuntil use.Multi-
plex ELISA was performed on supernatant by Quansys Biosciences (Logan,
UT) to detect IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70,
TNF-a, MIP-1a, MCP-1, GM-CSF, IFN-g, and RANTES. ELISAs were also per-
formed using CCL2 (MCP-1), CCL5 (RANTES), CXCL10 (IP-10), IL-1a, IL-6,
TNF-a, and IFN-g Duoset kits (R&D systems) as well as the VeriKine Mouse
Interferon-Alpha and Interferon-Beta ELISA Kits (Pestka Biomedical Labora-
tories, Inc). For the quantification of mRNA chemokine expression, lungCell 146, 980–991, September 16, 2011 ª2011 Elsevier Inc. 989
endothelial cells were FACS purified to > 90%–95% purity, and mRNA was
purified using the RNeasy mini kit from QIAGEN. Prior to real-time PCR,
genomic DNA was digested and cDNA was made using the RT2 First Strand
Kit (C-03) according to manufacturer’s instructions (SA Biosciences, Fred-
erick, MD). cDNA (200 ng) was added to individual wells and quantified using
the RT2 profiler PCR Array according to the manufacturer’s instructions (SA
Biosciences, Frederick, MD).
Cellular Analysis by Flow Cytometry
Lungs were harvested from PBS-perfused mice and mechanically diced into
small tissue pieces using surgical scissors. Diced lungs were suspended in
4 ml of CDTI buffer (0.5 mg/ml collagenase from Clostridium histolyticum
type IV [Sigma], 0.1 mg/ml Dnase I from bovine pancreas grade II [Roche],
1 mg/ml trypsin inhibitor type Ii-s [Sigma] in DMEM) for 1 hr at 37C. Lung
was then disrupted mechanically through a 100 mm filter, and red blood cells
were lysed using red blood cell lysis buffer (0.02 Tris-HCL and 0.14 NH4Cl).
Inflammatory cells were purified by centrifugation in 35%PBS-bufferedPercoll
(GE Healthcare Life Sciences) at 1,500 rpm for 15 min. Cell pellets were resus-
pended in staining buffer, and Fc receptors were blocked using 25 mg/ml anti-
mouse CD16/32 (BD Biosciences). Cells were stained with the following
anti-mouse antibodies: AlexaFluor 488-conjugated gp38 (eBioscience; clone
eBio8.1.1), PE-conjugated (BioLegend, Inc.; clone ME13.3) and APC-
conjugated (eBioscience; clone 390) CD31, PE-Cy7-conjugated EpCAM
(BioLegend, Inc.; clone 68.8), Pacific blue-conjugated CD45.2 (BioLegend,
Inc.; clone 104), PerCP-Cy5.5-conjugated NK1.1 (BD Biosciences; clone
PK136), PE-Cy7-conjugated CD3e (eBioscience; clone 145-2C11), e450-
conjugated CD4 (eBioscience; clone L3T4), PE-conjugated CD8a (BD Biosci-
ences; clone 53-6.1), Pacific blue-conjugated B220 (BD Biosciences; clone
RA3-6B2), PE-conjugated CD19 (BD Biosciences, clone 1D3), PE-Cy7-
conjugated CD11b (eBiosciences; clone M1/70), PerCP-Cy5.5-conjugated
CD11c (eBiosciences; clone N418), APC-conjugated Gr-1 (BD Biosciences;
clone RB6-8C5), Pacific blue and PE-conjugated Ly6G (BDBiosciences; clone
IA8), APC-conjugated F480 (eBioscience; clone BM8), PE-conjugated 7/4
(AbD Serotec; clone 7/4), PE-conjugated I/A-I/E (BD Biosciences; clone M5/
114.15.2), PE-Cy7 conjugated CD205 (eBiosciences; clone 205yekta), Fitc-
conjugated CD69 (BD Biosciences; clone H1.2F3), and APC-conjugated
CD25 (eBiosciences; clone PC61.5). Flow cytometry acquisition was per-
formedwith BD FACSDiva-driven BD LSR II flow cytometer (Becton, Dickinson
and Company). Data were then analyzed with FlowJo software (Treestar Inc.).
Western Blot
FACS-purified lung cell populations (1 3 105 cells) using the antibodies
described above were homogenized in RIPA buffer supplemented with
protease inhibitors (Pierce). Lysates were centrifuged at 50,000 3 g for
30 min, and the protein concentration in the supernatant was determined by
BCA assay (Pierce). Equal amounts of protein from cell lystates were loaded
in nondenaturing conditions and separated by SDS-PAGE in 4%–12%
NuPAGE (Novex) Bis-Tris gels. Gels were transferred to PVDF membranes
followed by probing for GFP using an anti-GFP antibody (Abcam) and an
anti-rabbit Ig light-chain HRP secondary (ELC Biosciences) using chemilumi-
nescence autoradiography.
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